Rat Model of Cardiotoxic Drug-Induced Cardiomyopathy.

[1]  P. Sengupta,et al.  Molecular Imaging of Apoptosis in Cancer Therapy-Related Cardiac Dysfunction Before LVEF Reduction. , 2018, JACC. Cardiovascular imaging.

[2]  D. Sawyer,et al.  Cardio-Oncology: An Update on Cardiotoxicity of Cancer-Related Treatment. , 2016, Circulation research.

[3]  Y. Azarmi,et al.  Cardioprotective Effect of Phenytoin on Doxorubicin-induced Cardiac Toxicity in a Rat Model , 2016, Journal of cardiovascular pharmacology.

[4]  M. Gheorghiade,et al.  Cancer Therapy–Related Cardiac Dysfunction and Heart Failure: Part 2: Prevention, Treatment, Guidelines, and Future Directions , 2016, Circulation. Heart failure.

[5]  J. Fragoso,et al.  Increased HDL Size and Enhanced Apo A-I Catabolic Rates Are Associated With Doxorubicin-Induced Proteinuria in New Zealand White Rabbits , 2016, Lipids.

[6]  Bonnie Ky,et al.  Cancer Therapy–Related Cardiac Dysfunction and Heart Failure: Part 1: Definitions, Pathophysiology, Risk Factors, and Imaging , 2016, Circulation. Heart failure.

[7]  L. Rochette,et al.  Paradoxically, iron overload does not potentiate doxorubicin-induced cardiotoxicity in vitro in cardiomyocytes and in vivo in mice. , 2015, Toxicology and applied pharmacology.

[8]  G. Akolkar,et al.  The role of renin angiotensin system antagonists in the prevention of doxorubicin and trastuzumab induced cardiotoxicity , 2015, Cardiovascular Ultrasound.

[9]  W. Pao,et al.  Disparities by Race, Age, and Sex in the Improvement of Survival for Major Cancers: Results From the National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) Program in the United States, 1990 to 2010. , 2015, JAMA oncology.

[10]  B. Tamarappoo,et al.  Noninvasive Molecular Imaging of Apoptosis in a Mouse Model of Anthracycline-Induced Cardiotoxicity , 2015, Circulation. Cardiovascular imaging.

[11]  S. Zhang,et al.  Cardiac Protective Effects of Dexrazoxane on Animal Cardiotoxicity Model Induced by Anthracycline Combined With Trastuzumab Is Associated With Upregulation of Calpain-2 , 2015, Medicine.

[12]  A. Fernandez-Fernandez,et al.  Chemotherapy-Induced Changes in Cardiac Capillary Permeability Measured by Fluorescent Multiple Indicator Dilution , 2014, Annals of Biomedical Engineering.

[13]  V. Ferrari,et al.  Concomitant low-dose doxorubicin treatment and exercise. , 2014, American journal of physiology. Regulatory, integrative and comparative physiology.

[14]  J. Radford,et al.  An integrated characterization of serological, pathological, and functional events in doxorubicin-induced cardiotoxicity. , 2014, Toxicological sciences : an official journal of the Society of Toxicology.

[15]  M. Capogrossi,et al.  Doxorubicin and trastuzumab regimen induces biventricular failure in mice. , 2014, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[16]  N. Kourda,et al.  Means of evaluation and protection from doxorubicin-induced cardiotoxicity and hepatotoxicity in rats. , 2014, Journal of cancer research and therapeutics.

[17]  S. Lim.  Interrelation between Expression of ADAM 10 and MMP 9 and Synthesis of Peroxynitrite in Doxorubicin Induced Cardiomyopathy , 2013, Biomolecules & therapeutics.

[18]  V. Dolinsky,et al.  Both aerobic exercise and resveratrol supplementation attenuate doxorubicin-induced cardiac injury in mice. , 2013, American journal of physiology. Endocrinology and metabolism.

[19]  D. A. Gomes,et al.  Doxorubicin Cardiotoxicity and Cardiac Function Improvement After Stem Cell Therapy Diagnosed by Strain Echocardiography. , 2013, Journal of cancer science & therapy.

[20]  Randolph P. Martin,et al.  Assessment of Echocardiography and Biomarkers for the Extended Prediction of Cardiotoxicity in Patients Treated With Anthracyclines, Taxanes, and Trastuzumab , 2012, Circulation. Cardiovascular imaging.

[21]  L. Druhan,et al.  Heat Shock Protein 25-Enriched Plasma Transfusion Preconditions the Heart against Doxorubicin-Induced Dilated Cardiomyopathy in Mice , 2012, Journal of Pharmacology and Experimental Therapeutics.

[22]  A. Maitra,et al.  A composite polymer nanoparticle overcomes multidrug resistance and ameliorates doxorubicin-associated cardiomyopathy , 2012, Oncotarget.

[23]  Mina Kim,et al.  Cardioprotective effects of rosuvastatin and carvedilol on delayed cardiotoxicity of doxorubicin in rats , 2012, Toxicology mechanisms and methods.

[24]  Xu Zhang,et al.  Heart fatty acid-binding protein may not be an early biomarker for anthracycline-induced cardiotoxicity in rabbits , 2012, Medical Oncology.

[25]  Renchun Lai,et al.  Oxidative stress markers may not be early markers of doxorubicin-induced cardiotoxicity in rabbits. , 2011, Experimental and therapeutic medicine.

[26]  A. Connolly,et al.  Pretreatment with angiotensin-converting enzyme inhibitor improves doxorubicin-induced cardiomyopathy via preservation of mitochondrial function. , 2011, The Journal of thoracic and cardiovascular surgery.

[27]  D. Jassal,et al.  The cardioprotective role of probucol against anthracycline and trastuzumab-mediated cardiotoxicity. , 2011, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[28]  F. Veglia,et al.  Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  W. Hundley,et al.  Novel Approach to Early Detection of Doxorubicin Cardiotoxicity by Gadolinium-Enhanced Cardiovascular Magnetic Resonance Imaging in an Experimental Model , 2010, Circulation. Cardiovascular imaging.

[30]  V. P. Chacko,et al.  Reduced in vivo high-energy phosphates precede adriamycin-induced cardiac dysfunction. , 2010, American journal of physiology. Heart and circulatory physiology.

[31]  B. Chow,et al.  Alterations of pre- and postsynaptic noradrenergic signaling in a rat model of adriamycin-induced cardiotoxicity , 2010, Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology.

[32]  K. Nishigaki,et al.  Anti-Fas gene therapy prevents doxorubicin-induced acute cardiotoxicity through mechanisms independent of apoptosis. , 2010, The American journal of pathology.

[33]  A. Sagie,et al.  Adenosine A3 receptor-mediated cardioprotection against doxorubicin-induced mitochondrial damage. , 2010, Biochemical pharmacology.

[34]  D. Jassal,et al.  Utility of tissue Doppler and strain rate imaging in the early detection of trastuzumab and anthracycline mediated cardiomyopathy. , 2009, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[35]  Differential roles of nitric oxide synthase isozymes in cardiotoxicity and mortality following chronic doxorubicin treatment in mice , 2009, Naunyn-Schmiedeberg's Archives of Pharmacology.

[36]  D. Hydock,et al.  Anandamide Preserves Cardiac Function and Geometry in an Acute Doxorubicin Cardiotoxicity Rat Model , 2009, Journal of cardiovascular pharmacology and therapeutics.

[37]  P. Kolattukudy,et al.  Cardiac-Targeted Expression of Soluble Fas Attenuates Doxorubicin-Induced Cardiotoxicity in Mice , 2009, Journal of Pharmacology and Experimental Therapeutics.

[38]  B. Yeğen,et al.  Resveratrol treatment protects against doxorubicin-induced cardiotoxicity by alleviating oxidative damage , 2009, Free radical research.

[39]  W. Shou,et al.  A Mouse Model for Juvenile Doxorubicin-Induced Cardiac Dysfunction , 2008, Pediatric Research.

[40]  D. Hydock,et al.  Exercise preconditioning protects against doxorubicin-induced cardiac dysfunction. , 2008, Medicine and science in sports and exercise.

[41]  A. Haholu,et al.  Hyperbaric oxygen therapy does not potentiate doxorubicin-induced cardiotoxicity in rats. , 2008, Basic & clinical pharmacology & toxicology.

[42]  D. Hydock,et al.  Doxorubicin cardiotoxicity in the rat: an in vivo characterization. , 2007, Journal of the American Association for Laboratory Animal Science : JAALAS.

[43]  R. Russell,et al.  Effect of lycopene on doxorubicin-induced cardiotoxicity: an echocardiographic, histological and morphometrical assessment. , 2007, Basic & clinical pharmacology & toxicology.

[44]  N. Narula,et al.  Potentiation of Doxorubicin cardiotoxicity by iron loading in a rodent model. , 2007, Journal of the American College of Cardiology.

[45]  Yumin Chen,et al.  Phenylbutyrate, a histone deacetylase inhibitor, protects against Adriamycin-induced cardiac injury. , 2007, Free radical biology & medicine.

[46]  W. Chan,et al.  Thrombopoietin Protects Against In Vitro and In Vivo Cardiotoxicity Induced by Doxorubicin , 2006, Circulation.

[47]  R. Shohet,et al.  Transcriptional analysis of doxorubicin-induced cardiotoxicity. , 2006, American journal of physiology. Heart and circulatory physiology.

[48]  W. Manning,et al.  Heterozygous knockout of neuregulin-1 gene in mice exacerbates doxorubicin-induced heart failure. , 2005, American journal of physiology. Heart and circulatory physiology.

[49]  T. Ertay,et al.  Radiopharmaceutical model using99mTc-MIBI to evaluate amifostine protection against doxorubicin cardiotoxicity in rats , 2005, Annals of nuclear medicine.

[50]  O. Mian,et al.  Targeted disruption of p53 attenuates doxorubicin-induced cardiac toxicity in mice , 2005, Molecular and Cellular Biochemistry.

[51]  S. Köse,et al.  Effect of octreotide in the prevention of doxorubicin cardiotoxicity. , 2005, Anadolu kardiyoloji dergisi : AKD = the Anatolian journal of cardiology.

[52]  G. Martinelli,et al.  Prognostic Value of Troponin I in Cardiac Risk Stratification of Cancer Patients Undergoing High-Dose Chemotherapy , 2004, Circulation.

[53]  Roelof J Bennink,et al.  Annexin V imaging of acute doxorubicin cardiotoxicity (apoptosis) in rats. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[54]  Tsuneyuki Nakamura,et al.  Troponin-T and brain natriuretic peptide as predictors for adriamycin-induced cardiomyopathy in rats. , 2004, Circulation journal : official journal of the Japanese Circulation Society.

[55]  C. Granier,et al.  Evaluation of cardiac troponin I and T levels as markers of myocardial damage in doxorubicin-induced cardiomyopathy rats, and their relationship with echocardiographic and histological findings. , 2003, Clinica chimica acta; international journal of clinical chemistry.

[56]  R. Olson,et al.  Doxorubicin and C-13 deoxydoxorubicin effects on ryanodine receptor gene expression. , 2002, Biochemical and biophysical research communications.

[57]  Tsuneyuki Nakamura,et al.  Apoptosis in Young Rats with Adriamycin-Induced Cardiomyopathy—Comparison with Pirarubicin, a New Anthracycline Derivative , 2002, Pediatric Research.

[58]  J. Bauer,et al.  Cardiac peroxynitrite formation and left ventricular dysfunction following doxorubicin treatment in mice. , 2000, The Journal of pharmacology and experimental therapeutics.

[59]  C. Carrasco,et al.  Assessment of anthracycline cardiomyopathy by endomyocardial biopsy. , 1994, Ultrastructural pathology.

[60]  J. Mason,et al.  Anthracycline cardiomyopathy monitored by morphologic changes. , 1978, Cancer treatment reports.

[61]  M. Billingham,et al.  Doxorubicin cardiotoxicity. Serial endomyocardial biopsies and systolic time intervals. , 1978, JAMA.

[62]  R Gorlin,et al.  Problems in echocardiographic volume determinations: echocardiographic-angiographic correlations in the presence of absence of asynergy. , 1976, The American journal of cardiology.